Novartis points to Zolgensma long-term benefits amid data scandalNovartis has new data in hand for spinal muscular atrophy (SMA) gene therapy Zolgensma that it hopes will Share XNovartis points to Zolgensma long-term benefits amid data scandalhttps://pharmaphorum.com/news/novartis-points-to-zolgensmas-long-term-benefits-amid-data-scandal/
Novartis’ Cosentyx heads for fourth indicationNovartis’ Cosentyx could be heading for a fourth indication after the company published late-stage trial data showing it Share XNovartis’ Cosentyx heads for fourth indicationhttps://pharmaphorum.com/news/cosentyx-heads-for/
Novartis backs brolucizumab with new head-to-head Eylea trialNovartis is launching a head-to-head trial of its experimental brolucizumab therapy for age-related macular degeneration (AMD) against Bayer/Regeneron’s Share XNovartis backs brolucizumab with new head-to-head Eylea trialhttps://pharmaphorum.com/news/novartis-backs-brolucizumab-with-new-head-to-head-eylea-trial/
Mixed reviews for Amgen’s KRAS drug after lung cancer data revealEagerly awaited trial data from Amgen’s latest KRAS-targeting cancer drug AMG 510 emerged over the weekend – and Share XMixed reviews for Amgen’s KRAS drug after lung cancer data revealhttps://pharmaphorum.com/news/mixed-reviews-for-amgens-kras-drug-after-lung-cancer-data-reveal/
Novartis’ lung cancer drug edges closer to market after FDA grants fast reviewAn investigational lung cancer drug from Novartis and Incyte could be on the market midway through next year Share XNovartis’ lung cancer drug edges closer to market after FDA grants fast reviewhttps://pharmaphorum.com/news/novartis-incytes-lung/
NHS funds eye gene therapy, after Novartis cuts £613,000 priceNICE has recommended the NHS should fund Novartis’ Luxturna for a rare eye disorder, after the company agreed Share XNHS funds eye gene therapy, after Novartis cuts £613,000 pricehttps://pharmaphorum.com/news/nhs-funds-eye-gene-therapy-after-novartis-cuts-613000-price/
Novartis strikes marketing deal for Polpharma’s potential Tysabri biosimilarNovartis’ biosimilars and generics arm Sandoz has struck a deal with Polpharma Biologics to market a proposed biosimilar Share XNovartis strikes marketing deal for Polpharma’s potential Tysabri biosimilarhttps://pharmaphorum.com/news/novartis-strikes-marketing-deal-for-polpharmas-potential-tysabri-biosimilar/
Despite trial miss, Novartis still believes in Entresto for HFpEFNovartis was expecting a lot from its PARAGON-HF trial of Entresto in heart failure with preserved ejection fraction Share XDespite trial miss, Novartis still believes in Entresto for HFpEFhttps://pharmaphorum.com/news/despite-trial-miss-novartis-still-believes-in-entresto-for-hfpef/
Novartis looks set to repurpose cancer drug in MS after trial winsNovartis has announced data supporting a cancer drug it acquired from GlaxoSmithKline and Genmab in a new use Share XNovartis looks set to repurpose cancer drug in MS after trial winshttps://pharmaphorum.com/news/novartis-looks-set-to-repurpose-cancer-drug-in-ms-after-trial-wins/
